<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159195</url>
  </required_header>
  <id_info>
    <org_study_id>A5481090</org_study_id>
    <secondary_id>IRIS</secondary_id>
    <nct_id>NCT03159195</nct_id>
  </id_info>
  <brief_title>Ibrance Real World Insights [IRIS]</brief_title>
  <acronym>IRIS</acronym>
  <official_title>TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS RECEIVING PALBOCICLIB COMBINATIONS FOR HR+/HER2- ADVANCED/METASTATIC BREAST CANCER IN REAL WORLD SETTINGS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe patient demographics, clinical characteristics, treatment patterns and clinical
      outcomes of adult female patients who have received palbociclib combination treatments in
      line with regional licensed indications in real world settings across multiple countries.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">June 3, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 3, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of patients progression free</measure>
    <time_frame>0 to 36 months</time_frame>
    <description>Proportion of patients who are progression free will be assessed at various timepoints between 0 and 36 months</description>
  </primary_outcome>
  <enrollment type="Actual">700</enrollment>
  <condition>Malignant Neoplasm of Breast</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>CDK 4/6 inhibitor for advanced/ metastatic breast cancer</description>
    <other_name>Ibrance</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult female patients with HR+/HER2 advanced or metastatic breast cancer receiving
        palbociclib combination regimens as per the approved indication.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  â‰¥18 years old

          -  HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.

          -  Received palbociclib plus letrozole/aromatase inhibitor or palbociclib plus
             fulvestrant in line with the licenced indication(s)

          -  No prior or current enrolment in an interventional clinical trial for ABC/MBC

          -  Minimum of three months of follow up data since palbociclib with fulvestrant
             initiation, or minimum of six months of follow up data since palbociclib with
             letrozole/aromatase inhibitor initiation (core medical record review)

          -  Minimum of three months of follow up data since palbociclib initiation (interim
             medical record review)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female participants only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481090&amp;StudyName=Treatment+Patterns+And+Clinical+Outcomes+Among+Patients+Receiving+Palbociclib+Combinations+For+Hr%2B%2Fher2-+Advanced%2Fmetastatic+Breast+Cancer+In+Real+World+Settings</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>advanced breast cancer</keyword>
  <keyword>HR+/ HER2-</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

